本报告导读：公司积极推进“赢得分子”战略，临床前业务高增，新增项目持续增长，剥离爱尔兰疫苗工厂，优化资产配置，看好长期成长空间，维持“增持”评级。投资要点：维持“增持”评级。公司发布 2024年财报，2024年营收 186.8亿元（+9.6%），净利润33.6 亿元（-1.3%），经调整净利润54.0 亿元（+9.0%），2024H2 营收101.0 亿元（+18.3%），净利润18.6 亿元（+...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.